A 12-week international, multicenter, open label, non-comparative study to evaulate the feasibility of switching any antipsychotic treatment to sustained-release quetiapine fumarate (Seroquel) in patients with schizophrenia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Jan 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quetiapine (Primary) ; Antipsychotics
Indications Schizophrenia
Focus Therapeutic Use
Sponsors AstraZeneca

Most Recent Events

29 Apr 2009 Cost-utility analysis based on this study published in Current Medical Research and Opinion, Mar, 2009.
31 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight